Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, a clinical-stage biopharmaceutical company, filed an S-1 to IPO on Nasdaq under the symbol "RTSN." The company is developing RTN-001, a next-generation once-daily oral PDE-5 inhibitor for uncontrolled and resistant hypertension. RTN-001 has been tested in 243 participants across nine completed trials, with two Phase 2 pilot trials showing clinically meaningful placebo-adjusted blood pressure reductions and no drug-related SAEs. A Phase 2b dose-ranging trial initiated in October 2025 with initial data expected in H1 2027. The filing discloses a restatement of FY2025
<

Price data unavailable.

A pre-revenue biotech targeting the massive 120-million-patient U.S. hypertension market is going public with a restated financial history and a material weakness — a high-risk, high-reward setup hing

The hypertension market is massive — an estimated 120 million U.S. adults have hypertension — yet first-generation PDE-5 inhibitors like sildenafil failed to achieve meaningful blood pressure reductions. Retension's engineered bioavailability approach targets the central vasculature, a niche that no

The company restated its FY2025 consolidated financial statements to correct an error and disclosed a material weakness in internal control over financial reporting — a red flag for a pre-IPO company. RTN-001 is still mid-stage with no Phase 3 data; the Phase 2b trial results won't arrive until H1 2